Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Document 8369092
Document related concepts
no text concepts found
Transcript
Biomarker for Colorectal Cancer Overview The pathogenesis of 15% of human cancers has been linked to inflamma:on. One of the most prevalent inflamma:on driven cancers is coli:s-‐associated colorectal cancer (CRC). Annually in Ireland -‐ CRC is responsible for 15% of all cancer related deaths with an average of 1445 cases. What Problem does it Solve / Advantages Be(er Diagnosis Early stages of progression to CRC, par:cularly dis:nguishing between inflamma:on and true dysplasia, is not as straighOorward, and there is a large amount of varia:on between pathologists iden:fica:on and grading of dysplasia. There is a serious requirement for an addi:onal early marker of dysplasia in this context, and the role and expression of enzyme proteins involved in inflamma:on has been examined. Pa:ents who have had coli:s for >10 years are advised to undergo regular colonoscopy to detect preinvasive neoplas:c lesions High grade inflamma:on is also regarded as an indica:on for colectomy. The increased expression of enzyme proteins ‘caspases-‐4’ and ‘Caspase -‐5 ‘ correlated to inflamma:on and disease ac:vity in irritable bowel disease and CRC pa:ents. Clinical Advantages Improved accuracy of diagnosis, early treatment, reduc:on in colectomies and improvement in quality of life Market Diagnos:cs IP Status Priority Applica:on filed EP14182681.8 Opportunity Research collabora:on, Available to license Researcher(s) Emma Creagh Elaine Kay Elizabeth Ryan Glen Doherty Caspase 4 Contact Dr. Emily Vereker, Case Manager, Life Sciences Image source: www.sdsmexecu:vehealth.com/colorectal-‐cancer/ [email protected] Caspase 5 +353 1 896 4152 Normal Tissue TumourTissue Technology/Patent Status A priority patent has been filed with the European patent office EP14182681.8 Reference: EC01-‐493-‐01
